mRNA-4157,Pembrolizumab
Moderna,Merck
['keytruda']
at #asco23 - phase 3 trial to confirm promising results from phase 2 trial of mrna vaccine + adjuvant keytruda will be launched. early data reported prolonged time to recurrence, metastasis or death in resected stage iii/iv patients who received the vaccine combination. 
The Melanoma Research Foundation (MRF) is the largest independent organization devoted to #melanoma. Help us find pathways to a cure! #GetNaked